01
Blood-Based Testing
The microRNA test uses a 3 mL blood sample. Tumor marker testing is performed at the same time.
NEXT GENERATION CANCER RISK TEST
A whole-body risk checkfor long-term health and mobility
In addition to blood-based microRNA methylation analysis, we perform sex-specific tumor marker testing to assess risk signals associated with 17 types of cancer. We offer this as one option for patients who want to consider their overall health in addition to musculoskeletal treatment and rehabilitation.
3 mL blood sample for microRNA testing
No fasting required
Risk assessment for 17 cancer types
98.9%
Sensitivity reported in an Asian study population
FOR ACTIVE LIFE
To keep moving well,
pay attention to your whole-body health.
Caring for joints, muscles, and other parts of the musculoskeletal system is important, but maintaining your overall health also matters if you want to stay active in the years ahead. At TGOC, we offer a blood-based cancer risk test as one option for broader health assessment.
The test requires only a blood sample and does not require fasting. Blood collection itself takes about five minutes, so the test can also be performed during a clinic or rehabilitation visit.
A physician will explain your results and, when needed, recommend additional testing or referral to an appropriate medical facility.
FEATURES
Four Key Features of the Test
02
No Fasting Required
No dietary restriction or fasting is required before the test.
03
17 Cancer Types
The test assesses risk signals associated with multiple types of cancer.
04
Results Explained by a Physician
A physician reviews your results and explains any recommended next steps.
CLINICAL DATA
Test Performance Reported in anAsian Study Population
Cancer-patient group · Asian study population
98.9%
1,145 positive results among 1,158 samples
| Group | Samples | Positive | Reported Metric |
|---|---|---|---|
| Cancer patients | 1,158 | 1,145 | 98.9% |
| Non-cancer / healthy individuals | 644 | 16 | 97.5% |
*The materials provided report a sensitivity of 99.4% when head and neck cancer cases are excluded. The available performance data were obtained from an Asian study population. Performance may vary across different ethnic and geographic populations, and this test is not intended to provide a definitive diagnosis of cancer.
How the Test Works
- The test focuses on changes in microRNAs, which help regulate gene activity.
- It analyzes changes in microRNA methylation associated with cancer development.
- Mass spectrometry is used to examine these molecular-level changes.
Illustrative Comparison of microRNA Methylation Levels
*Illustrative data visualizing blood microRNA methylation levels.
17 CANCER TYPES
Cancer Types Included:17 Types
Digestive System (6)
Stomach cancer · Colorectal cancer
Liver cancer · Pancreatic cancer
Esophageal cancer · Biliary tract cancer
Respiratory & Head/Neck (4)
Lung cancer · Pharyngeal cancer
Laryngeal cancer · Thyroid cancer
Breast, Gynecologic & Urologic (7)
Breast cancer · Ovarian cancer
Cervical cancer · Endometrial cancer · Kidney cancer
Bladder cancer · Prostate cancer
*This test alone cannot diagnose a specific cancer. Depending on the results, a physician may recommend additional testing.
ADDITIONAL BLOOD MARKERS
In Addition to microRNA Analysis,
Tumor Marker TestingIs Also Performed
At TGOC, microRNA methylation testing is combined with tumor marker testing selected according to sex. We review multiple blood-based indicators together and recommend additional evaluation when appropriate.
microRNA methylation analysis + tumor marker testing
Rather than relying on a single result, the physician evaluates multiple findings together.
Rather than relying on a single result, the physician evaluates multiple findings together.
Female
Tumor MarkerMainly Associated Cancers
- CA19-9Pancreatic · Biliary tract · Stomach
- CEAColorectal · Stomach · Pancreatic · Lung, etc.
- AFPHepatocellular carcinoma · Germ cell tumors
- PIVKA-ⅡHepatocellular carcinoma
- CA125Ovarian · Cervical
- CYFRA21-1Lung cancer
- SCC AntigenCervical · Esophageal and other squamous cell carcinomas
- CA15-3Breast cancer
- hCGChoriocarcinoma · Germ cell tumors
Male
Tumor MarkerMainly Associated Cancers
- CA19-9Pancreatic · Biliary tract · Stomach
- CEAColorectal · Stomach · Pancreatic · Lung, etc.
- AFPHepatocellular carcinoma · Germ cell tumors
- PIVKA-ⅡHepatocellular carcinoma
- CYFRA21-1Lung cancer
- SCC AntigenEsophageal · Lung and other squamous cell carcinomas
- hCGGerm cell tumors, including testicular tumors
- PSAProstate cancer
*The cancers listed are examples commonly associated with each tumor marker. Tumor markers may also be elevated in benign conditions, and they may remain normal even when cancer is present. Tumor marker values alone cannot confirm or rule out cancer. A physician interprets them together with the microRNA methylation test and clinical findings.
TEST PROCESS
TestProcess
1
Consultation
A physician explains the test
2
Blood Draw
About 5 minutes · No fasting required
3
Laboratory Analysis
The sample is analyzed in detail
4
Results
A physician explains the results in approximately 1 month
Important Information Before Testing
- This test does not provide a definitive diagnosis of cancer.
- A negative result does not completely rule out the presence of cancer.
- This test is not a substitute for standard cancer screening recommended by public health authorities or medical societies.
- Blood collection may rarely cause pain, bruising, or lightheadedness.
- Depending on the results, we may recommend additional imaging or detailed evaluation at a specialist medical facility.
Interested in the Cancer Risk Test?
Please book a regular new-patient or follow-up consultation. During your visit, a physician will explain the test and confirm whether it is appropriate for you.